Cargando…

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis

This randomized, double-blind study assessed the antifracture efficacy and safety of intermittent intravenous (IV) ibandronate versus oral daily risedronate in Japanese patients with primary osteoporosis. Ambulatory patients aged ≥60 years were randomized to receive 0.5 or 1 mg/month IV ibandronate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Toshitaka, Nakano, Tetsuo, Ito, Masako, Hagino, Hiroshi, Hashimoto, Junko, Tobinai, Masato, Mizunuma, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717162/ https://www.ncbi.nlm.nih.gov/pubmed/23644930 http://dx.doi.org/10.1007/s00223-013-9734-6

Ejemplares similares

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis
por: Nakamura, T., et al.
Publicado: (2015)

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
por: Hagino, Hiroshi, et al.
Publicado: (2014)

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis
por: Rackoff, Paula
Publicado: (2009)

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012)

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
por: Nakai, Kiyohiko, et al.
Publicado: (2014)

Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
por: Casado, Enrique, et al.
Publicado: (2023)

Preparation and Characterization of Mg–Al–B Alloy (Mg(0.5)Al(0.5)B(2)) Via High-Temperature Sintering
por: Yang, Lin, et al.
Publicado: (2021)

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis
por: Yoo, Jun-Il, et al.
Publicado: (2017)

Crystal chemistry and compressibility of Fe(0.5)Mg(0.5)Al(0.5)Si(0.5)O(3) and FeMg(0.5)Si(0.5)O(3) silicate perovskites at pressures up to 95 GPa
por: Koemets, Iuliia, et al.
Publicado: (2023)

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data
por: McClung, M. R., et al.
Publicado: (2012)

Li(0.5)Al(0.5)Mg(2)(MoO(4))(3)
por: Ennajeh, Ines, et al.
Publicado: (2013)

Surface Modification of Biomedical MgCa(4.5) and MgCa(4.5)Gd(0.5) Alloys by Micro-Arc Oxidation
por: Sakiewicz, Piotr, et al.
Publicado: (2021)

Cardiovascular effect of dental anesthesia with articaine (40 mg with epinefrine 0,5 mg % and 40 mg with epinefrine 1 mg%) versus mepivacaine (30mg and 20 mg with epinefrine 1 mg%) in medically compromised cardiac patients: A cross-over, randomized, single blinded study
por: Torres-Lagares, Daniel, et al.
Publicado: (2012)

Effect of Mg Contents on the Microstructure, Mechanical Properties and Cytocompatibility of Degradable Zn-0.5Mn-xMg Alloy
por: Yang, Lingbo, et al.
Publicado: (2023)

Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy
por: Sung, Jidong, et al.
Publicado: (2016)

Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus ≥0.5-mg/kg/d dosing in acne patients: A systematic review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine
por: Dahlöf, Carl, et al.
Publicado: (2004)

Comparison of the anesthetic effects between 5 mg/kg of alfaxalone and 10 mg/kg of propofol administered intravenously in cats
por: TAMURA, Jun, et al.
Publicado: (2021)

Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Lee, Young Ho, et al.
Publicado: (2011)

Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery
por: Carbonell Esteve, Josep L, et al.
Publicado: (2012)

Characterization and Properties of Mg-xGd-1.5Nd-0.5Zn-0.5Zr Alloys for Biodegradation Applications
por: Gui, Zhenzhen, et al.
Publicado: (2020)

Modified electroconvulsive therapy in a resource-challenged setting: Comparison of two doses (0.5 mg/kg and 1 mg/kg) of suxamethonium chloride
por: Aaron, Olurotimi I., et al.
Publicado: (2020)

Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis
por: Takeuchi, Yasuhiro, et al.
Publicado: (2018)

Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes
por: Torimoto, Keiichi, et al.
Publicado: (2013)

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
por: Sambrook, Philip
Publicado: (2007)

Hot Deformation Behavior, Processing Maps and Microstructural Evolution of the Mg-2.5Nd-0.5Zn-0.5Zr Alloy
por: Ma, Junfei, et al.
Publicado: (2022)

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
por: McClung, M. R., et al.
Publicado: (2011)

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
por: Prünte, Christian, et al.
Publicado: (2016)

Electrochemical Analysis and In Vitro Assay of Mg-0.5Ca-xY Biodegradable Alloys
por: Istrate, Bogdan, et al.
Publicado: (2020)

Study of physical properties of the Li(0.5)MgFe(1.5)O(3.5) ferrite nanoparticles
por: Jeidd, Abddaim, et al.
Publicado: (2023)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

Effect of heat treatment on corrosion behavior of Mg–5Gd–3Y–0.5Zr alloy
por: Zhang, Qian, et al.
Publicado: (2020)

Annealing-Dependent Morphotropic Phase Boundary in the BiMg(0.5)Ti(0.5)O(3)–BiZn(0.5)Ti(0.5)O(3) Perovskite System
por: Cardoso, João Pedro V., et al.
Publicado: (2022)

The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg
por: Schrader, J, et al.
Publicado: (2009)

Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial
por: Allais, G, et al.
Publicado: (2015)

Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers
por: Fossler, Michael J., et al.
Publicado: (2015)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

Annealing Temperature Effects on Humidity Sensor Properties for Mg(0.5)W(0.5)Fe(2)O(4) Spinel Ferrite
por: Petrila, Iulian, et al.
Publicado: (2022)

A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis
por: Horikawa, Akira, et al.
Publicado: (2019)

Pharmacokinetic Studies in Elasmobranchs: Meloxicam Administered at 0.5 mg/kg Using Intravenous, Intramuscular, and Oral Routes to Nursehound Sharks (Scyliorhinus stellaris)
por: Morón-Elorza, Pablo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ks91bgni1ss81iasikpjbr4st8